Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab vs Active Control in Pediatric XLH
NCT02915705Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of burosumab in X-linked hypophosphatemia (XLH) (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Radiographic Global Impression of Change Global Score at 40 weeks. Started Sep 2016; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT02915705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915705.